Metsera, Inc./$MTSR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Metsera, Inc.

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Ticker

$MTSR
Sector
Primary listing

Employees

107

Metsera, Inc. Metrics

BasicAdvanced
$5.6B
-
-$5.89
-
-

Bulls say / Bears say

MET-097i delivered an average weight loss of 11.3% in a mid-stage trial, showing strong results compared to current GLP-1 therapies. (Reuters)
Early-stage results for MET-233i indicated a potentially best-in-class profile, highlighting differentiation for its amylin analog candidate. (Reuters)
Pfizer’s proposed buyout values Metsera at up to $7.3 billion, a 42.5% premium to its pre-deal share price, confirming the strategic importance of its obesity pipeline. (Reuters)
Metsera’s lead candidates are still in early-stage development and have no approved products, signaling that commercial revenue is unlikely before the late 2020s. (Reuters)
The acquisition’s contingent value rights of up to $22.50 per share depend on meeting milestones and getting regulatory approvals, which introduces both execution and valuation risk. (Reuters)
Strong competition from GLP-1 leaders Novo Nordisk and Eli Lilly may put pressure on market share and pricing for Metsera’s future therapies. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MTSR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs